Asia Pacific Cell Culture Market

The Asia Pacific cell culture market is projected to reach USD 12.40 billion by 2030 from USD 6.98 billion in 2025, with a CAGR of 12.2% during the forecast period. Several major factors are driving increased demand in the cell culture market in the Asia-Pacific region. These include the rapid expansion of biopharmaceutical manufacturing, the growing number of clinical research activities, and rising investment in drug discovery in countries such as China, India, and South Korea.

To know about the assumptions considered for the study download the pdf brochure

The Asia Pacific cell culture market is consolidated. Prominent players in the Asia Pacific cell culture market are Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Sartorius AG (Germany), Danaher (US), FUJIFILM Holdings Corporation (Japan), and HiMedia Laboratories (India), among others.

In July 2024, Merck invested approximately USD 7.1 million (EUR 6.6 million) in the expansion of its commercial production of the first GMP-compliant manufacturing line for cell culture media (CCM) in China.

Thermo Fisher Scientific Inc. (US) holds a significant market share in the Asia Pacific cell culture market, mainly due to its comprehensive localization strategy across China, India, Japan, and Southeast Asia. The company actively supports rapidly expanding CROs, CDMOs, and emerging biotech firms by offering scalable, cost-efficient cell culture consumables and integrated workflows. Thermo Fisher's early engagement with academic and government research institutes in the Asia Pacific has helped build long-term adoption of its platforms. Additionally, its ability to serve both early-stage research and commercial manufacturing needs positions it firmly in fast-growing APAC life sciences ecosystems.

Merck KGaA (Germany) is a key player in the Asia Pacific cell culture market, driven by its focus on high-growth therapeutic areas, including biosimilars, vaccines, and cell and gene therapies, which are rapidly expanding across Asia. The company has prioritized supply chain resilience and regional production to support high-volume demand from local biopharma manufacturers. Merck's technical expertise and customized media solutions are particularly valued by APAC customers transitioning from small-scale research to industrial-scale production. Its strong engagement with regulatory and quality-focused manufacturers further enhances its regional market position.

Sartorius AG (Germany) maintains a dominant position in the Asia Pacific cell culture market as the region is rapidly developing a need for an efficient, space-saving, and flexible bioprocessing infrastructure. Its disposable bioreactors and modular cell culture systems are compatible with Asia Pacific manufacturers who are scaling up biologics and biosimilars. At the same time, they want to control the costs and the constraints of the ?‍?‌‍?‍‌?‍?‌‍?‍‌facility. Sartorius benefits from increasing investments in domestic biomanufacturing capabilities across China, South Korea, and India. The company/ s emphasis on process intensification and automation aligns closely with the Asia Pacific’s push toward faster time-to-market and manufacturing efficiency.

Market Ranking

The Asia Pacific cell culture market is moderately consolidated, driven by the rapid expansion of biopharmaceutical manufacturing and rising demand from emerging biotech hubs across China, India, South Korea, and Southeast Asia. In line with high demand for cell culture in the region, Thermo Fisher Scientific remains a significant contributor to the Asia Pacific market with the strong customer usage of its Gibco cell culture media, sera, and supplements products, and also its ability to supply affordable and scalable solutions that are suitable for both early-stage research and commercial ?‍?‌‍?‍‌?‍?‌‍?‍‌production. Merck KGaA holds a strong position due to its emphasis on chemically defined and regulatory-ready media, supported by a growing regional manufacturing and supply presence that serves local biologics and biosimilar producers. Sartorius is a key competitor in the Asia Pacific region, leveraging its upstream cell culture and single-use bioprocess platforms, which align well with the region's focus on rapid capacity expansion, facility flexibility, and efficient scale-up. Across the Asia Pacific, buyers are increasingly prioritizing localized supply, regulatory readiness, and scalable workflows, thereby reinforcing the dominance of established global suppliers.

Related Reports:

Asia Pacific Cell Culture Market by Product [Consumable {Media, Sera, Reagent, Vessel (Roller Bottle, Flask, Cell Factory)}, Equipment {Bioreactor, Centrifuge, Filtration, Incubator}], Application [mAb, Vaccine, CGT], End User - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com